Long Non-Coding RNAs (lncRNAs) in Cardiovascular Disease Complication of Type 2 Diabetes.
Nurruzanna IsmailNoraidatulakma AbdullahNor Azian Abdul MuradRahman JamalSiti Aishah SulaimanPublished in: Diagnostics (Basel, Switzerland) (2021)
The discovery of non-coding RNAs (ncRNAs) has opened a new paradigm to use ncRNAs as biomarkers to detect disease progression. Long non-coding RNAs (lncRNA) have garnered the most attention due to their specific cell-origin and their existence in biological fluids. Type 2 diabetes patients will develop cardiovascular disease (CVD) complications, and CVD remains the top risk factor for mortality. Understanding the lncRNA roles in T2D and CVD conditions will allow the future use of lncRNAs to detect CVD complications before the symptoms appear. This review aimed to discuss the roles of lncRNAs in T2D and CVD conditions and their diagnostic potential as molecular biomarkers for CVD complications in T2D.
Keyphrases
- long non coding rna
- cardiovascular disease
- type diabetes
- poor prognosis
- risk factors
- end stage renal disease
- newly diagnosed
- cardiovascular events
- ejection fraction
- chronic kidney disease
- small molecule
- insulin resistance
- network analysis
- prognostic factors
- stem cells
- single cell
- metabolic syndrome
- high throughput
- cell therapy
- peritoneal dialysis
- mesenchymal stem cells
- long noncoding rna
- transcription factor
- climate change
- single molecule
- human health
- sleep quality
- physical activity